Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Howard Hughes Medical Institute, Lexicon Pharmaceuticals, Nuevolution to collaborate with Duke University

Nuevolution : 13 August, 2013  (Company News)
Nuevolution enters into a scientific collaboration with Duke University, the Howard Hughes Medical Institute, and Lexicon Pharmaceuticals, for the investigation of the biological mechanism of action of a specified GPCR drug target.


The principal investigator for Duke University and the Howard Hughes Medical Institute is Robert Lefkowitz, a Duke Faculty member and HHMI employee and Nobel Laureate in Chemistry 2012.



During the scientific collaboration, Nuevolution will provide access to its proprietary Chemetics  technology for small molecule drug discovery and both Nuevolution and Lexicon will provide access to selected chemical libraries created using the Chemetics technology. Within the framework of the collaboration, hundreds of millions of diverse small molecules will be screened in the endeavor to discover compounds with certain novel and unique properties against the GPCR drug target.



"We are excited to enter into this scientific collaboration with the renowned and world-leading scientific group of Dr. Lefkowitz and our dedicated partner Lexicon Pharmaceuticals," said Thomas Franch, Chief Scientific Officer of Nuevolution. "If successful, this highly challenging project may cast new and very important light on the mechanism of action of GPCRs."



"We have used the Chemetics technology successfully to identify novel chemotypes for our internal programmes and are enthusiastic about exploring the utility of our DNA-tagged libraries of diverse chemical compounds in the screening of GPCRs. We look forward to working with Nuevolution and Dr Lefkowitz's team at Duke University on this project," said Brian Zambrowicz, PhD, Executive Vice President and Chief Scientific Officer of Lexicon.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo